Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.

Li-Li Deng; Hong-Bin Deng; Chang-Lian Lu; Yang Guo; Di Wang; Chun-Hua Yan; Xing Lv; Yu-Xia Shao

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.

【24h】

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.

机译：EGFR或KRAS突变以及基于IIIB和IV期无法手术的非小细胞肺癌的小型活检样本的化学疗法相关基因的表达。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Mutations and expression of chemotherapy-related genes may provide a basis for the selection of suitable molecular markers for individual treatment in a population with stage IIIB and IV NSCLC.

机译：化疗相关基因的突变和表达可为选择合适的分子标记物提供基础，以用于IIIB期和IV期NSCLC人群的个体治疗。

著录项

来源
《Journal of Cancer Research and Clinical Oncology》 |2014年第12期|共9页
作者
Li-Li Deng; Hong-Bin Deng; Chang-Lian Lu; Yang Guo; Di Wang; Chun-Hua Yan; Xing Lv; Yu-Xia Shao;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. [J] . Li-Li Deng, Hong-Bin Deng, Chang-Lian Lu, Journal of Cancer Research and Clinical Oncology . 2014,第12期

机译：EGFR或KRAS突变以及基于IIIB和IV期无法手术的非小细胞肺癌的小型活检样本的化学疗法相关基因的表达。
2. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). [J] . Lim EH, Zhang SL, Li JL, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2009,第1期

机译：使用小批量活检的全基因组扩增（WGA）评估EGFR，KRAS，p53和CMET突变在晚期非小细胞肺癌（NSCLC）中的预后作用。
3. A phase II study of sorafenib in patients with platinum-pretreated, advanced (stage IIIb or IV) non-small cell lung cancer with a KRAS mutation [J] . DingemansA.-M.C., MellemaW.W., GroenH.J.M., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第3期

机译：索拉非尼在患有铂预处理，晚期（IIIb或IV期）KRAS突变的非小细胞肺癌患者中的II期研究
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11 KRAS and TP53 mutations and co-mutations on outcome [O] . Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti, 2021

机译：下一代测序液体活检在免疫检查点抑制剂治疗的先进非小细胞肺癌患者中的作用：STK11KRAS和TP53突变的影响和共生突变
7. P2-066: Analysis of EGFR gene copy number, EGFR mutations, KRAS mutations and EGFR expression in a cohort of non-small cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors at a North American institution. [O] . Box Alan K., Otsuka Shannon, Morris Don, 2007

机译：P2-066：在北美一家机构中对使用表皮生长因子酪氨酸激酶抑制剂治疗的非小细胞肺癌患者队列中的EGFR基因拷贝数，EGFR突变，KRAS突变和EGFR表达进行了分析。

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅